Correction: Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.

Autor: Kloos A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Mintzas K; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Winckler L; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Gabdoulline R; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Alwie Y; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Jyotsana N; Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA., Kattre N; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Schottmann R; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Scherr M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Gupta C; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Adams FF; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany., Schwarzer A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany., Heckl D; Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.; Department of Pediatric Hematology and Oncology, Martin-Luther-University Halle-Wittenberg, Halle, Germany., Schambach A; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Imren S; Department of Pediatrics, University of Washington, Seattle, WA, USA., Humphries RK; Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.; Department of Medicine, University of British Columbia, Vancouver, BC, Canada., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Thol F; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. heuser.michael@mh-hannover.de.

Publikováno v: Leukemia [Leukemia] 2021 Dec; Vol. 35 (12), pp. 3629.

Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.

Autor: Kloos A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Mintzas K; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Winckler L; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Gabdoulline R; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Alwie Y; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Jyotsana N; Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA., Kattre N; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Schottmann R; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Scherr M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Gupta C; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Adams FF; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany., Schwarzer A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany., Heckl D; Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.; Department of Pediatric Hematology and Oncology, Martin-Luther-University Halle-Wittenberg, Halle, Germany., Schambach A; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Imren S; Department of Pediatrics, University of Washington, Seattle, WA, USA., Humphries RK; Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.; Department of Medicine, University of British Columbia, Vancouver, BC, Canada., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Thol F; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. heuser.michael@mh-hannover.de.

Publikováno v: Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 2951-2963. Date of Electronic Publication: 2020 Jun 24.

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.

Autor: Chaturvedi A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Goparaju R; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Gupta C; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Weder J; Institute for Biophysical Chemistry, Hannover Medical School, Hannover and Centre for Structural Systems Biology, Hamburg, Germany., Klünemann T; Institute for Biophysical Chemistry, Hannover Medical School, Hannover and Centre for Structural Systems Biology, Hamburg, Germany., Araujo Cruz MM; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Kloos A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Goerlich K; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Schottmann R; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Othman B; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Struys EA; Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands., Bähre H; Research Core Unit Metabolomics, Institute of Pharmacology, Hannover Medical School, Hannover, Germany., Grote-Koska D; Institute of Clinical Chemistry, Hannover Medical School, Hannover, Germany., Brand K; Institute of Clinical Chemistry, Hannover Medical School, Hannover, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Preller M; Institute for Biophysical Chemistry, Hannover Medical School, Hannover and Centre for Structural Systems Biology, Hamburg, Germany. preller.matthias@mh-hannover.de., Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. heuser.michael@mh-hannover.de.

Publikováno v: Leukemia [Leukemia] 2020 Feb; Vol. 34 (2), pp. 416-426. Date of Electronic Publication: 2019 Oct 04.

Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes

Autor: Schottmann R, Alfons Lampen, A Linck, Augustinus Bader, Uwe Christians, Karl-Friedrich Sewing, Gudrun Schmidt

Publikováno v: British Journal of Clinical Pharmacology. 41:187-190

1. Tacrolimus, an immunosuppressive macrolide, is metabolized by enzymes of the cytochrome P450 3A subfamily. In this study, 34 drugs were tested for their interactions with tacrolimus metabolism by human liver microsomes. 2. Fifteen drugs which inhi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c610e73a0cbd1fac026f858bfb894dd9
https://doi.org/10.1111/j.1365-2125.1996.tb00181.x

Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors—Recent Advances, Challenges and Future Prospects.

Autor: Kowalczyk, Adrian¹ (AUTHOR) adriankowalczyk31@gmail.com, Zarychta, Julia¹ (AUTHOR) julia.zarychta99@gmail.com, Lejman, Monika² (AUTHOR) monika.lejman@umlub.pl, Latoch, Eryk³ (AUTHOR) eryk.latoch@umb.edu.pl, Zawitkowska, Joanna⁴ (AUTHOR) joannazawitkowska@umlub.pl

Publikováno v: International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 14, p7916. 24p.